Drug intelligence / Profile preview

MK-0893 + sitagliptin

Development stage: Discontinued
Lead developer: Merck
Modality: Small Molecules
Administration: Oral

Overview

MK-0893 + sitagliptin is an investigational combination of two oral small molecule drugs for type 2 diabetes. **MK-0893** is a glucagon receptor antagonist that works by blocking the glucagon receptor, thereby reducing hepatic glucose output. **Sitagliptin** is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases endogenous incretin levels (GLP-1, GIP), promoting insulin release and decreasing glucagon secretion in response to food. The combination is designed to act synergistically to improve glycemic control by reducing both hepatic glucose production and increasing insulin-dependent glucose clearance.

Other names: L-001241689L001241689L 001241689

Targets

DPP-4 (Dipeptidyl Peptidase-IV)GCGR (Glucagon receptor)

Beyond the preview

Go deeper on MK-0893 + sitagliptin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MK-0893 + sitagliptin.

Explore the full profile